Pharmaceutics (May 2021)

New Approaches in Nanomedicine for Ischemic Stroke

  • Clara Correa-Paz,
  • Andrés da Silva-Candal,
  • Ester Polo,
  • Jérôme Parcq,
  • Denis Vivien,
  • Dusica Maysinger,
  • Beatriz Pelaz,
  • Francisco Campos

DOI
https://doi.org/10.3390/pharmaceutics13050757
Journal volume & issue
Vol. 13, no. 5
p. 757

Abstract

Read online

Ischemic stroke, caused by the interruption of blood flow to the brain and subsequent neuronal death, represents one of the main causes of disability in developed countries. Therapeutic methods such as recanalization approaches, neuroprotective drugs, or recovery strategies have been widely developed to improve the patient’s outcome; however, important limitations such as a narrow therapeutic window, the ability to reach brain targets, or drug side effects constitute some of the main aspects that limit the clinical applicability of the current treatments. Nanotechnology has emerged as a promising tool to overcome many of these drug limitations and improve the efficacy of treatments for neurological diseases such as stroke. The use of nanoparticles as a contrast agent or as drug carriers to a specific target are some of the most common approaches developed in nanomedicine for stroke. Throughout this review, we have summarized our experience of using nanotechnology tools for the study of stroke and the search for novel therapies.

Keywords